Jump to ContentJump to Main Navigation
Imaging the Aging Brain$
Users without a subscription are not able to see the full content.

William Jagust and Mark D'Esposito

Print publication date: 2009

Print ISBN-13: 9780195328875

Published to Oxford Scholarship Online: February 2010

DOI: 10.1093/acprof:oso/9780195328875.001.0001

Show Summary Details
Page of

PRINTED FROM OXFORD SCHOLARSHIP ONLINE (www.oxfordscholarship.com). (c) Copyright Oxford University Press, 2019. All Rights Reserved. An individual user may print out a PDF of a single chapter of a monograph in OSO for personal use. date: 16 September 2019

The Early Detection of Alzheimer's Disease with Positron Emission Tomography

The Early Detection of Alzheimer's Disease with Positron Emission Tomography

Chapter:
(p.151) 11 The Early Detection of Alzheimer's Disease with Positron Emission Tomography
Source:
Imaging the Aging Brain
Author(s):

Rachel Mistur

Lisa Mosconi

Remigiusz Switalski

Susan De Santi

Yi Li

Lidia Glodzik

Miroslaw Brys

Wai Tsui

Henry Rusinek

Mony J. de Leon

Publisher:
Oxford University Press
DOI:10.1093/acprof:oso/9780195328875.003.0011

Reductions in the cerebral metabolic rate of glucose (CMRglc), a measure of neuronal function, have proven to be a promising tool in the early diagnosis of Alzheimer's disease (AD). FDG-PET imaging demonstrates progressive CMRglc reductions in AD patients, the extent and topography of which correlate with symptom severity. There is increasing evidence that hypometabolism appears during the preclinical stages of AD and can predict decline years before the onset of symptoms. This chapter provides an overview of FDG-PET results in individuals at risk for developing dementia, including presymptomatic individuals carrying mutations responsible for early-onset familial AD, patients with mild cognitive impairment (MCI), nondemented carriers of the Apolipoprotein E (ApoE) e4 allele, cognitively normal subjects with a family history of AD, subjects with subjective memory complaints, and the normal elderly followed longitudinally until they expressed the clinical symptoms of AD. Finally, this chapter discusses the potential to combine different PET tracers and cerebrospinal fluid (CSF) markers of pathology to improve the early detection of AD.

Keywords:   Alzheimer's disease, FDG-PET, hypometabolism, preclinical diagnosis, cerebrospinal fluid (CSF), mild cognitive impairment, apolipoprotein E (ApoE), normal aging

Oxford Scholarship Online requires a subscription or purchase to access the full text of books within the service. Public users can however freely search the site and view the abstracts and keywords for each book and chapter.

Please, subscribe or login to access full text content.

If you think you should have access to this title, please contact your librarian.

To troubleshoot, please check our FAQs , and if you can't find the answer there, please contact us .